Altimmune Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Insider Trading Arrangements
On December 23, 2024, Dr. M. Scot Roberts, our Chief Scientific Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 269,831 shares of our common stock acquired pursuant to our Employee Stock Purchase Plan and the vesting and exercise of stock options and restricted stock units granted to Dr. Roberts. Dr. Robert’s plan will commence on the later
of March 24, 2025 or twobusiness days following the filing of our financial results on Form 10-K, and expires on March 24, 2026.
During the year ended December 31, 2024, other than the trading arrangement disclosed above, none of our officers or directors adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
We have adopted insider trading policies and procedures governing the purchase, sale, and/or other dispositions of our securities by us, directors, officers and employees.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.